Metagenomi Therapeutics (MGX) Cash from Financing Activities (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Cash from Financing Activities of -$27000.0 for Q1 2026, up 64.94% year-over-year from -$16370.1 in Q1 2025, and down 136.49% quarter-over-quarter from $74000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Cash from Financing Activities data on file, last reported at -$27000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$27000.0, up 64.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$306000.0 (up 88.24% YoY), and the FY2025 annual result was -$356000.0, down 100.42% from the prior year.
- Cash from Financing Activities fell to -$27000.0 in Q1 2026 per MGX's latest filing, from $74000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $86.5 million in Q1 2024 and troughed at -$2.0 million in Q2 2024.
- A 4-year average of $7.1 million and a median of -$121500.0 in 2025 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 1914.83% in 2024 and fell as far as 5110.26% in 2024.
- A 4-year view of Cash from Financing Activities shows it stood at -$1.3 million in 2023, then jumped by 63.12% to -$492000.0 in 2024, then soared by 115.04% to $74000.0 in 2025, then tumbled by 136.49% to -$27000.0 in 2026.
- Business Quant data shows MGX's Cash from Financing Activities at -$27000.0 in Q1 2026, $74000.0 in Q4 2025, and -$187000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | 85,464.43 |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Sep 30, 2025 | -187,000.00 |
| Sep 30, 2025 | -187,000.00 |
| Jun 30, 2025 | -166,000.00 |
| Jun 30, 2025 | -166,000.00 |
| Mar 31, 2025 | -77,000.00 |
| Mar 31, 2025 | -77,000.00 |
| Sep 30, 2024 | -492,000.00 |
| Sep 30, 2024 | -492,000.00 |
| Jun 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -2.03 Mn |
| Mar 31, 2024 | 86.54 Mn |
| Mar 31, 2024 | 86.54 Mn |
| Dec 31, 2023 | -1.33 Mn |
| Dec 31, 2023 | -1.33 Mn |
| Sep 30, 2023 | -1.91 Mn |
| Sep 30, 2023 | -1.91 Mn |